Clinical trials: Nonsmall Cell Lung Cancer, Stage II
Non-small-cell Lung Cancer
A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer
This is a Phase I-II study designed to investigate nimotuzumab (TheraCIM h-R3) in combination with external radiation in patients with non-small cell lung cancer.
- Trial name
- NCT00369447
- Testing
- External radiotherapy, nimotuzumab
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 52 people
- Sponsor
- YM BioSciences
Lung Cancer (NSCLC)
Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients
This is a single arm, open-label exploratory study conducted in resectable stage II-IIIA NSCLC without EGFR/ALK mutations, aiming to investigate feasibility, safety and efficacy of Sugemalimab in perioperative contexts.
- Trial name
- NCT06987734
- Testing
- Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Resectable Stage II-IIIB NSCLC
A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)
In recent years, substantial progress has been made in the development of perioperative immunotherapy for non-small cell lung cancer (NSCLC).
- Trial name
- NCT07108816
- Testing
- Neoadjuvant Sacituzumab tirumotecan + tagitanlimab Followed by adjuvant tagitanlimab
- Volunteers
- 52 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer Stage IIIB, ALK Gene Mutation
Alectinib Pharmacokinetic in Patients With NSCLC
This interventional study aims to determine the pharmacokinetics of orally administered alectinib with dose escalation from 300 mg to 600 mg twice daily in Mexican patients with advanced ALK-positive NSCLC.
- Trial name
- NCT05713006
- Testing
- Alectinib Oral Product
- Where
- Mexico
- Volunteers
- 45 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
Stage IV Lung Cancer
Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer
Current therapies for Stage IV Lung Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV Pancreatic Cancer.
- Trial name
- NCT00003492
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
This phase I/II trial studies the side effects and best dose of vorinostat when given together with paclitaxel and radiation therapy and to see how well it works in treating patients unable to tolerate cisplatin with stage III…
- Trial name
- NCT00662311
- Testing
- vorinostat, paclitaxel, radiation therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Carcinoma, Non-Small-Cell Lung
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
This is a research study to test the effectiveness of nab-paclitaxel + carboplatin + MPDL3280A for treatment of non-small-cell lung carcinoma (NSCLC), which is a type of lung cancer.
- Trial name
- NCT02716038
- Testing
- MPDL3280A, Carboplatin, Nab-paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Columbia University
Lung Cancer
Carboplatin and Gemcitabine Combined With Celecoxib and/or Zileuton in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00070486
- Testing
- carboplatin, celecoxib, gemcitabine hydrochloride
- Where
- 75 sites in United States
- Volunteers
- 140 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage II-III Non-small Cell Lung Cancer
Neoadjuvant Therapy of SBRT Sequencial With Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable…
- Trial name
- neoR-TORCH (NCT06437977)
- Testing
- SBRT, Toripalimab
- Where
- China
- Volunteers
- 478 people
- Sponsor
- Shanghai Chest Hospital
NSCLC Stage IV, Brain Metastases
SRS Sequential Sindilimab in Brain Metastasis of NSLSC
A phase II study on the treatment of advanced non-small cell lung cancer with brain metastasis by SRS sequential sintilimab
- Conditions
- NSCLC Stage IV, Brain Metastases, SRS, Sintilimab
- Trial name
- NCT04180501
- Testing
- SRS sequential sintilimab
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Xiaorong Dong
Lung Cancer
Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003900
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)
This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer.
- Conditions
- Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
- Trial name
- ANVIL (NCT02595944)
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 884 sites in United States
- Volunteers
- 903 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung, Thoracic Surgery, Video-Assisted
VATS Lobectomy for Clinical Stage IB or II Lung Cancer
To examine the feasibility of VATS lobectomy for clinical stage IB or II non-small cell lung cancer. Success is defined as VATS lobectomy without conversion.
- Trial name
- NCT00425022
- Testing
- thoracoscopy
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- National Cancer Center, Korea
STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER
A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer
The purpose of this study is to determine whether Bortezomib is effective in the treatment of patients with non-small-cell lung cancer who have not received any prior chemotherapy regimen for advanced disease.
- Trial name
- NCT00346645
- Testing
- Bortezomid (VELCADE®)
- Where
- France
- Volunteers
- 46 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Cancer Cachexia
A Clinical Study With MT-102 in Subjects With Cancer Cachexia
A phase II clinical study to evaluate MT-102 administered over a sixteen week period in subjects with cachexia related to non-small cell lung cancer and colorectal cancer
- Trial name
- NCT01238107
- Testing
- MT-102
- Where
- 18 sites in Germany, India and 1 more
- Volunteers
- 87 people
- Sponsor
- Akamis Bio
Lung Cancer
Hypofractionated 3-Dimensional Radiation Therapy in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer. ICORG 99-09
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor over a shorter period of time may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00955175
- Testing
- hypofractionated radiation therapy
- Where
- Ireland
- Volunteers
- 60 people
- Sponsor
- Cancer Trials Ireland
Non-Small Cell Lung Cancer Stage
Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
The purpose of this study is to assess the response rate to neoadjuvant Compound 121564 plus platinum doublet chemotherapy in patients with early stage non-small cell lung cancer.
- Trial name
- NCT03480230
- Testing
- Compound 121564
- Where
- 5 sites in Jordan, Lebanon
- Volunteers
- 60 people
- Sponsor
- Arafat Tfayli
Carcinoma, Non-small-cell Lung
Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)
Primary objective is to assess the overall response rate (ORR) after induction therapy with docetaxel in combination with CDDP and cetuximab in patients with NSCLC stage IB, II, and IIIa.
- Trial name
- NCT00406302
- Testing
- Docetaxel, oxaliplatin, cetuximab
- Where
- 7 sites in Austria
- Volunteers
- 41 people
- Sponsor
- Wolfgang Hilbe
Lung Cancer
Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of cancer cells and slow the growth of the tumor.
- Trial name
- NCT00062062
- Testing
- carboplatin, gefitinib, paclitaxel
- Where
- 141 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Non-small Cell Lung Cancer
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine if the combination of cetuximab, carboplatin and paclitaxel will shrink a specific type of lung cancer known as non-small cell lung cancer (NSCLC).
- Trial name
- NCT00097227
- Testing
- Cetuximab, Carboplatin, Paclitaxel
- Where
- 20 sites in United States
- Volunteers
- 165 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.